A Study to Assess Efficacy, Safety and Pharmacokinetics of a Tacrolimus New Oral Formulation (MR4) in BMT Recipients
NCT00189761 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL
Last updated 2006-09-20
Summary
A study to assess efficacy, safety and pharmacokinetics of a tacrolimus new oral formulation (MR4) in de novo bone marrow transplant recipients
Conditions
- Bone Marrow Transplantation
- Graft Versus Host Disease
- Graft-Vs-Host Disease
- Graft-Versus-Host Disease
Interventions
- DRUG
Sponsors & Collaborators
-
Astellas Pharma Inc
lead INDUSTRY
Principal Investigators
-
Clinical development · Astellas Pharma Inc., Japan
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 20 Years
- Max Age
- 54 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- Japan
More Related Trials
-
Use of Sublingual Tacrolimus in Adult Blood and Marrow Transplant Patients
NCT04041219 ·Status: COMPLETED ·Phase: PHASE4
-
Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease
NCT01713400 ·Status: COMPLETED ·Phase: PHASE2
-
Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies
NCT02556931 ·Status: COMPLETED ·Phase: PHASE2
-
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
NCT02793544 ·Status: COMPLETED ·Phase: PHASE2
-
Tacrolimus in Allogeneic Hematopoietic Stem Cell Transplant (HCT)
NCT04645667 ·Status: COMPLETED
-
Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation
NCT01338987 ·Status: COMPLETED ·Phase: PHASE2
-
Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation
NCT00096096 ·Status: COMPLETED ·Phase: PHASE2
-
Observational Study of the Combination of Post-transplant High Dose Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Acute Graft-versus-Host Disease in Patients Eligible to Allogeneic Hematopoietic Stem Cell Transplant
NCT02300571 ·Status: UNKNOWN
-
Bone Marrow Transplant With Abatacept for Non-Malignant Diseases
NCT01917708 ·Status: COMPLETED ·Phase: PHASE1
-
Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic Cancer
NCT00255710 ·Status: COMPLETED ·Phase: PHASE1
-
Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia
NCT02845596 ·Status: COMPLETED ·Phase: NA
-
Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant
NCT03459170 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants
NCT05364762 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bone Marrow Failures
NCT04232085 ·Status: RECRUITING ·Phase: PHASE2
-
Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor
NCT02500550 ·Status: COMPLETED ·Phase: PHASE2
-
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity
NCT04339777 ·Status: RECRUITING ·Phase: PHASE2
-
A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)
NCT05600426 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Pharmacokinetics-based Mycophenolate Mofetil Dosing for GVHD Prevention
NCT01487577 ·Status: COMPLETED ·Phase: PHASE2
-
Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders
NCT03579875 ·Status: RECRUITING ·Phase: PHASE2
-
Active Immunization of Sibling Bone Marrow Transplant Donors Against Purified Myeloma Protein of the Recipient Undergoing Allogeneic Bone Marrow Transplantation
NCT00001561 ·Status: COMPLETED ·Phase: PHASE3
-
Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
NCT06839456 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Early Use of Tacrolimus in HLA-Mismatched Haploidentical Allogeneic Hematopoietic Transplantation With Post-Transplant Cyclophosphamide
NCT06828796 ·Status: RECRUITING ·Phase: PHASE2
-
Safety Study of Bone Marrow Transplant Using Mismatched Tissue Followed by Chemotherapy
NCT00796562 ·Status: COMPLETED ·Phase: PHASE2
-
Budesonide for Prevention of Acute Gastrointestinal GVHD Following Allogenic Stem Cell Transplantation
NCT00180089 ·Status: COMPLETED ·Phase: PHASE3
-
Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide
NCT01342289 ·Status: COMPLETED ·Phase: PHASE1